BACKGROUND: Breast cancer in young women is typically characterised by aggressive disease, and treatment with adjuvant chemotherapy is generally recommended. Chemotherapy has conferred significant improvements in disease-free and overall survival for young women with breast cancer; however, with improved cure rates, long-term adverse effects of cytotoxic treatment, such as premature ovarian failure (POF) and infertility, have become increasingly important. A potential fertility preservation strategy is administration of gonadotropin-releasing hormone agonists (GnRHas) during adjuvant chemotherapy. DESIGN: This review analyses and summarises the current evidence for use of GnRHa in preserving ovarian function in young breast cancer patients. RESULTS: Twelve trials, both non-randomised and randomised, have now been conducted assessing GnRHas in fertility preservation in young breast cancer patients, with conflicting results. Limitations of the current data include the use of poorly sensitive end points for fertility preservation, variable age of enrolled patients and limited pregnancy data. CONCLUSION: The utility of GnRHa as a fertility preservation strategy remains uncertain, and use outside of a clinical trial generally not recommended. Further research into this under-recognised issue is vital.
BACKGROUND:Breast cancer in young women is typically characterised by aggressive disease, and treatment with adjuvant chemotherapy is generally recommended. Chemotherapy has conferred significant improvements in disease-free and overall survival for young women with breast cancer; however, with improved cure rates, long-term adverse effects of cytotoxic treatment, such as premature ovarian failure (POF) and infertility, have become increasingly important. A potential fertility preservation strategy is administration of gonadotropin-releasing hormone agonists (GnRHas) during adjuvant chemotherapy. DESIGN: This review analyses and summarises the current evidence for use of GnRHa in preserving ovarian function in young breast cancerpatients. RESULTS: Twelve trials, both non-randomised and randomised, have now been conducted assessing GnRHas in fertility preservation in young breast cancerpatients, with conflicting results. Limitations of the current data include the use of poorly sensitive end points for fertility preservation, variable age of enrolled patients and limited pregnancy data. CONCLUSION: The utility of GnRHa as a fertility preservation strategy remains uncertain, and use outside of a clinical trial generally not recommended. Further research into this under-recognised issue is vital.
Entities:
Keywords:
GNRH analogue; breast cancer; chemotherapy; fertility; young age
Authors: Kathryn J Ruddy; Shari I Gelber; Rulla M Tamimi; Elizabeth S Ginsburg; Lidia Schapira; Steven E Come; Virginia F Borges; Meghan E Meyer; Ann H Partridge Journal: J Clin Oncol Date: 2014-02-24 Impact factor: 44.544
Authors: Kate E Waimey; Brigid M Smith; Rafael Confino; Jacqueline S Jeruss; Mary Ellen Pavone Journal: J Womens Health (Larchmt) Date: 2015-06-15 Impact factor: 2.681
Authors: Halle C F Moore; Joseph M Unger; Kelly-Anne Phillips; Frances Boyle; Erika Hitre; David Porter; Prudence A Francis; Lori J Goldstein; Henry L Gomez; Carlos S Vallejos; Ann H Partridge; Shaker R Dakhil; Agustin A Garcia; Julie Gralow; Janine M Lombard; John F Forbes; Silvana Martino; William E Barlow; Carol J Fabian; Lori Minasian; Frank L Meyskens; Richard D Gelber; Gabriel N Hortobagyi; Kathy S Albain Journal: N Engl J Med Date: 2015-03-05 Impact factor: 91.245
Authors: Susan R Rose; Vincent E Horne; Jonathan Howell; Sarah A Lawson; Meilan M Rutter; Gylynthia E Trotman; Sarah D Corathers Journal: Nat Rev Endocrinol Date: 2016-04-01 Impact factor: 43.330